Literature DB >> 15011738

Nicotine dependence and psychiatric disorders.

Rafael J Salín-Pascual1, Natasha V Alcocer-Castillejos, Gabriel Alejo-Galarza.   

Abstract

Nicotine addiction is the single largest preventable cause of morbidity and mortality in the Western World. Smoking is not any more just a bad habit, but a substance addiction problem. The pharmacological aspects of nicotine show that this substance has a broad distribution in the different body compartnents, due mainly to its lipophilic characteristic. There are nicotinic receptors as members of cholinergic receptors' family. They are located in neuromuscular junction and in the central nervous system (CNS). Although they are similar, pentameric structure with an ionic channel to sodium, there are some differences in the protein chains characteristics. Repeated administration of nicotine in rats, results in the sensitization phenomenon, which produces increase in the behavioral locomotor activity response. It has been found that most psychostimulants-induced behavioral sensitization through a nicotine receptor activation. Nicotine receptors in CNS are located mainly in presynaptic membrane and in that way they regulated the release of several neurotransmitters, among them acetylcholine, dopamine, serotonin, and norepinephrine. In some activities like sleep-wake cycle, nicotine receptors have a functional significance. Nicotine receptor stimulation promotes wake time, reduces both, total sleep time and rapid eye movement sleep (REMS). About nicotine dependence, this substance full fills all the criteria for dependence and withdrawal syndrome. There are some people that have more vulnerability for to become nicotine dependent, those are psychiatric patients. Among them schizophrenia, major depression, anxiety disorders and attention deficit disorder, represent the best example in this area. Nicotine may have some beneficial effects, among them are some neuroprotective effects in disorders like Parkinson's disease, and Gilles de la Tourette' syndrome. Also there are several evidences that support the role of nicotine in cognitive improvement functions like attention, concentration, and memory. Finally there are several strategies to deal with nicotine dependence, Nicotine Replacement Therapy (NRT), which are nicotine chewing-gum, transdermal nicotine patches, and nicotine inhalators device. Also some antidepressants like bupropion has shown to be effective in smoking cessation treatment. To know more about nicotine phenomenon would be important, because that will allow a more mature perspective about the damage and beneficial effects of that substance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15011738

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  13 in total

1.  Nicotine exposure during adolescence: cognitive performance and brain gene expression in adult heterozygous reeler mice.

Authors:  Emilia Romano; Federica De Angelis; Lisa Ulbrich; Antonella De Jaco; Andrea Fuso; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2013-12-13       Impact factor: 4.530

Review 2.  [Nicotine. Influence on sleep and its relevance for psychiatry and psychotherapy].

Authors:  A Jähne; S Cohrs; A Rodenbeck; S Andreas; B Loessl; B Feige; C Kloepfer; M Hornyak; D Riemann
Journal:  Nervenarzt       Date:  2010-07       Impact factor: 1.214

3.  Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.

Authors:  Yann S Mineur; Oli Somenzi; Marina R Picciotto
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

4.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

5.  Nicotine dependence and mental disorders among adults in the USA: evaluating the role of the mode of administration.

Authors:  R D Goodwin; M J Zvolensky; K M Keyes
Journal:  Psychol Med       Date:  2008-03-26       Impact factor: 7.723

6.  Biological basis for the co-morbidity between smoking and mood disorders.

Authors:  Yann S Mineur; Marina R Picciotto
Journal:  J Dual Diagn       Date:  2009

7.  Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments.

Authors:  Morgane Besson; Stefania Guiducci; Sylvie Granon; Jean-Philippe Guilloux; Bruno Guiard; Christelle Repérant; Philippe Faure; Stéphanie Pons; Giuseppe Cannazza; Michele Zoli; Alain M Gardier; Uwe Maskos
Journal:  Psychopharmacology (Berl)       Date:  2016-07-06       Impact factor: 4.530

8.  ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure.

Authors:  Jingchun Chen; Darlene H Brunzell; Kia Jackson; Andrew van der Vaart; Jennie Z Ma; Thomas J Payne; Richard Sherva; Lindsay A Farrer; Pablo Gejman; Douglas F Levinson; Peter Holmans; Steven H Aggen; Imad Damaj; Po-Hsiu Kuo; Bradley T Webb; Raymond Anton; Henry R Kranzler; Joel Gelernter; Ming D Li; Kenneth S Kendler; Xiangning Chen
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

9.  Main clinical features in patients at their first psychiatric admission to Italian acute hospital psychiatric wards. The PERSEO study.

Authors:  Andrea Ballerini; Roberto M Boccalon; Giancarlo Boncompagni; Massimo Casacchia; Francesco Margari; Lina Minervini; Roberto Righi; Federico Russo; Andrea Salteri; Sonia Frediani; Andrea Rossi; Marco Scatigna
Journal:  BMC Psychiatry       Date:  2007-01-19       Impact factor: 3.630

10.  Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (psychiatric emergency study and epidemiology) survey.

Authors:  Andrea Ballerini; Roberto M Boccalon; Giancarlo Boncompagni; Massimo Casacchia; Francesco Margari; Lina Minervini; Roberto Righi; Federico Russo; Andrea Salteri; Sonia Frediani; Andrea Rossi; Marco Scatigna
Journal:  Ann Gen Psychiatry       Date:  2007-11-05       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.